Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Mylan Nv Ord Shs (MYL) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart


See More
  • Market Capitalization, $K 18,461,120
  • Shares Outstanding, K 534,910
  • Annual Sales, $ 9,429 M
  • Annual Income, $ 848 M
  • 36-Month Beta 1.08
  • Price/Sales 1.96
  • Price/Book 1.56

Price Performance

See More
Period Period Low Period High Performance
33.79 +9.03%
on 12/07/16
40.41 -8.83%
on 11/10/16
-2.08 (-5.34%)
since 11/09/16
33.60 +9.64%
on 11/03/16
43.72 -15.74%
on 09/22/16
-3.05 (-7.65%)
since 09/09/16
33.60 +9.64%
on 11/03/16
55.51 -33.63%
on 12/29/15
-13.86 (-27.34%)
since 12/09/15

Most Recent Stories

More News
Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs

Drug pricing is back in focus with president-elect Trump making it clear that he does not like price increases.

5 Drug Stocks to Avoid as Trump Vows to Lower Drug Prices

For those who thought that the pharma/biotech sector is in for an extraordinary run after Donald Trump's unexpected victory, his latest vow to crack down on excessive drug price hikes comes as a bolt from...

This Little Red Splotch Just Cost Investors Millions…

This post This Little Red Splotch Just Cost Investors Millions… appeared first on Daily Reckoning . The one sector getting “Trumped” and what your next move should be. Plus- Greg Guenthner shares...

Pfizer (PFE) Fined for Price Hike of Anti-Epilepsy Drug in UK

Pfizer (PFE) fined for hiking price of an anti-epilepsy drug by up to 2,600% by the Competition and Markets Authority of the UK.

Mylan (MYL) Stock Falls on Restructuring Plans, Layoffs

Mylan (MYL) has revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on integrating acquisitions.

Should Biotech Investors Worry About Donald Trump?

It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.

DEADLINE ALERT: Brower Piven Notifies Shareholders of Upcoming Deadline In Class Action Lawsuit And Urges Those With Losses In Excess of $100,000 From Investment In Mylan N.V. To Contact The Firm - MYL

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of...

Trump Vows to Slash Drug Prices, Sends Biotech Stocks Lower

Shares of the iShares Nasdaq Biotechnology ETF (IBB) are down more than 3.6% in morning trading Wednesday following a new warning from President-elect Donald Trump that he will indeed be targeting high...

Here's Why Teva Pharmaceutical's (TEVA) Stock Is Down Today

Shares of Teva Pharmaceutical Industries (TEVA) slipped over 5.8% in morning trading Tuesday after the company announced a change in upper-level management.

Rosen Law Firm Reminds Mylan N.V. Investors of Important Dec. 12 Deadline in Class Action Filed by Firm - MYL

Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Mylan Inc., predecessor of Mylan N.V., and/or Mylan N.V. ordinary shares (NASDAQ: MYL) from February 28, 2013 through...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Support & Resistance

2nd Resistance Point 37.30
1st Resistance Point 36.68
Last Price 36.77
1st Support Level 34.84
2nd Support Level 33.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.